Building AI Foundation Models for Molecular Design
About this episode
The episode discusses the launch of Boltz, an AI infrastructure company for molecular biology, and its impact on drug discovery and molecular design.
Cofounders Jeremy Wohlwend and Gabriele Corso join the a16z podcast to discuss the launch of Boltz, a public benefit company building AI infrastructure for molecular biology. The conversation explains how breakthroughs following AlphaFold moved the field beyond protein structure prediction into modeling biomolecular interactions and binding strength, why open-source Boltz models saw rapid adoption across pharma and biotech, and how that work is now being productized. They outline the launch of Boltz Lab, a platform that brings protein and small-molecule design agents into scientist workflows, Boltz’s decision to operate as an infrastructure company rather than a therapeutics company, and how AI could reduce early drug discovery bottlenecks by improving molecular design and speeding iteration between computation and the lab.
More episodes of Raising Health
- Healthcare Will Benefit Most from AI | Julie Yoo on StartUp Health
- Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity
- Rebuilding Behavioral Health’s Operating System with AI
- AI in Healthcare: The Leapfrog Opportunity
- Ambience CEO Nikhil Buduma on AI in Clinical Workflows
- Building the Marketplace for AI’s Most Valuable Asset
Explore listener stats, chart rankings, contacts and more on the Raising Health podcast page.